Global Endometriosis Treatment Market Report and Forecast 2023-2031

The global endometriosis treatment market size was estimated to be worth USD 1.44 billion in 2022. The market is expected to grow at a CAGR of 7.7% during the forecast period of 2023-2031 to attain a market value of USD 2.79 billion by 2031. The growth of the market is driven by the rising research and development activities.

Endometriosis Treatment Market: Introduction

Endometriosis is a medical condition in which the tissue lining the uterus grows outside the uterus, causing pain and discomfort. The condition is often associated with infertility, and it affects millions of women worldwide. The global endometriosis treatment market is highly competitive, with key players focusing on research and development activities to develop innovative products and strengthen their market position.

Endometriosis Epidemiology

Endometriosis is a common medical condition that affects women of reproductive age. It is estimated that approximately 10% of women worldwide are affected by endometriosis. The condition occurs when the tissue lining the uterus (endometrium) grows outside the uterus, leading to pain and discomfort.

Endometriosis is often misdiagnosed or undiagnosed, which leads to delayed diagnosis and treatment. The exact cause of endometriosis is unknown, but it is believed to be a combination of genetic and environmental factors. It is also more common among women who have never had children. Endometriosis can affect various parts of the body, including the ovaries, fallopian tubes, and the tissue lining the pelvis. The most common symptoms of endometriosis include pelvic pain, painful periods, pain during intercourse, and infertility.

The prevalence of endometriosis varies by region and age group. According to a systematic review and meta-analysis published in The Lancet in 2020, the global prevalence of endometriosis was estimated to be 1.7% (95% CI 1.5-1.9) among women of reproductive age. The prevalence was found to be highest in North America (2.6%, 95% CI 2.2-3.0) and lowest in Africa (1.0%, 95% CI 0.5-1.5).

The same study also found that the prevalence of endometriosis increased with age, peaking in women in their 40s. It was also found to be more common among women with infertility, chronic pelvic pain, and dysmenorrhea (painful periods).

Endometriosis Treatment Market Segmentations

The market can be categorised into indication type, diagnostic method, treatment method, drug class, and distribution channel.

Market Breakup by Indication Type

• Superficial Peritoneal Lesion
• Endometrioma
• Deeply Infiltrating Endometriosis
• Others

Market Breakup by Diagnostic Method

• Ultrasound
• Pelvic Examination
• Laparoscopy
• Magnetic Resonance Imaging
• Others

Market Breakup by Treatment Method

• Hormonal Therapy
• Pain Management
• Others

Endometriosis Treatment Market Breakup by Drug Class

• Oral Contraceptives
• Progestins
• NSAIDs
• GnRH Analogues
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Endometriosis Treatment Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Endometriosis Treatment Market Scenario

The global endometriosis treatment market is expected to witness significant growth during the forecast period of 2023-2031. The market is being driven by factors such as the increasing prevalence of endometriosis, growing awareness and diagnosis of the condition, and the availability of advanced treatments and therapies.

Hormonal therapy is the most commonly used treatment for endometriosis, followed by non-steroidal anti-inflammatory drugs (NSAIDs), gonadotropin-releasing hormone (GnRH) agonists, aromatase inhibitors, and progestins. Laparoscopy is the most common diagnostic method used to diagnose endometriosis.

North America dominates the endometriosis treatment market, followed by Europe and the Asia Pacific. The market in North America is driven by the high prevalence of endometriosis and the availability of advanced healthcare infrastructure. The market in Europe is also expected to grow significantly, with key players focusing on research and development activities to develop innovative products. The market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about endometriosis and the rising healthcare expenditure in the region.

Key Players in the Global Endometriosis Treatment Market

The report gives an in-depth analysis of the key players involved in the Endometriosis Treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Abbott
• AbbVie Inc
• Bayer AG
• Pfizer Inc
• Ipsen Pharma
• Evotec SE
• Myovant Sciences GmbH
• Philogen S.p.A
• Astellas Pharma Inc
• Orphagen Pharmaceuticals